According to IMARC Group, the global mRNA Vaccines and Therapeutics Market was valued at USD 60.58 Billion in 2025 and is projected to reach USD 75.11 Billion by 2034, exhibiting a CAGR of 2.30% during 2026–2034. This sustained growth trajectory is driven by expanding oncology pipelines, advancements in lipid nanoparticle (LNP) delivery systems, surging demand for personalized cancer vaccines, and the broadening application of mRNA technology across infectious diseases, rare genetic disorders, and gene therapy.

mRNA Vaccines and Therapeutics Market Overview

The mRNA vaccines and therapeutics market represents the intersection of synthetic biology, molecular medicine, and precision therapeutics. At its core, the platform leverages synthetic mRNA strands that encode instructions for the body's own cellular machinery to produce specific proteins — triggering immune responses or correcting disease-driving protein deficiencies without altering the patient's DNA.

The mRNA Vaccines and Therapeutics Market Size has grown substantially beyond its COVID-19 origins. Today, the platform spans multiple therapeutic modalities, including:

●        Prophylactic vaccines: COVID-19 boosters, RSV vaccines, seasonal influenza mRNA vaccine programmes

●        Personalized cancer vaccines: Patient-specific mRNA vaccines targeting tumour neoantigens

●        Gene editing and protein replacement therapies: Addressing enzyme-deficiency disorders and rare genetic diseases

●        Infectious disease therapeutics: mRNA-based treatments for Zika, chlamydia, and respiratory viruses

These applications are adopted across hospitals and clinics, research organizations, and global pharmaceutical manufacturers seeking to harness mRNA's speed, scalability, and adaptability advantages over traditional vaccine and drug development platforms.

Global Market Overview & mRNA Vaccines and Therapeutics Market Statistics

Below are the key mRNA Vaccines and Therapeutics Market statistics drawn from IMARC Group's comprehensive market analysis:

Key Market Drivers & mRNA Vaccines and Therapeutics Market Trends in 2026

Several powerful forces are shaping the mRNA vaccines and therapeutics market share landscape and fuelling growth expectations through 2034:

1. Growing Incidence of Chronic and Infectious Diseases

Rising cancer rates and re-emerging infectious diseases are the primary demand catalysts for mRNA therapeutics. Global cancer cases are projected to reach 35 million by 2050, driving intensive investment in personalized mRNA cancer vaccine development. Simultaneously, the RSV disease burden — killing up to 10,000 Americans annually and hospitalizing 1–2% of infants in the first six months of life — is accelerating demand for mRNA-based preventive and therapeutic solutions that offer faster development timelines and adaptability to emerging viral strains.

2. Advancements in Lipid Nanoparticle (LNP) Delivery Technology

LNP delivery systems remain the dominant mRNA delivery platform, protecting mRNA from degradation and enabling efficient cellular uptake through ionizable lipid-mediated endosomal escape. Continuous LNP innovation — including organ-targeted and extrahepatic delivery — is a key competitive differentiator. In August 2025, FDA approval of Pfizer-BioNTech's LP.8.1-adapted COVID-19 vaccine demonstrated evolving platform adaptability and growing regulatory confidence in mRNA delivery technology.

3. Rising Demand for Personalized Medicine

mRNA's programmable nature enables the rapid design of patient-specific cancer vaccines targeting unique tumour neoantigens. BioNTech's collaboration with the UK government to deliver personalized mRNA cancer immunotherapies for 10,000 patients by 2030 validates the commercial potential of this approach. Moderna's mRNA-4157 demonstrated a 44% reduction in melanoma recurrence risk in Phase 2b trials, opening a multi-billion-dollar precision oncology opportunity and reflecting a defining mRNA Vaccines and Therapeutics Market Trend.

4. AI-Powered mRNA Sequence Design and Optimization

Artificial intelligence is transforming mRNA vaccine development by dramatically accelerating codon optimization and sequence-stability prediction. Machine learning models now predict mRNA structure-stability relationships that previously required months of laboratory iteration. GenScript's May 2025 launch of GMP-like mRNA manufacturing services integrating digital-biology platforms is shortening development timelines. AI-enabled sequence optimization is expected to halve next-generation mRNA cancer vaccine development timelines.

5. Self-Amplifying mRNA (saRNA) Platform Emergence

Self-amplifying mRNA platforms enable equivalent immune responses at doses 10–100x lower than conventional mRNA by replicating within cells, dramatically reducing manufacturing requirements and cost per dose. CSL Limited's collaboration with Arcturus Therapeutics to access the saRNA vaccine platform — and Arcturus' first-approved saRNA COVID vaccine in the EU in 2025 — mark pivotal commercial validation of this cost-advantage platform for pandemic preparedness and emerging market access.

6. Rapid Regulatory Approvals and Streamlined Pathways

Streamlined FDA, EMA, and PMDA regulatory pathways established during the COVID-19 pandemic are accelerating mRNA product commercialization across multiple therapeutic areas. The institutional trust built in mRNA platform safety and efficacy is enabling more rapid progression of clinical programmes in oncology, rare diseases, and respiratory viruses — a key structural tailwind for the mRNA Vaccines and Therapeutics Market Trends landscape.

7. Expansion into Rare Genetic Diseases and Gene Therapy

mRNA therapeutics are advancing beyond infectious disease vaccines into rare genetic disorders and gene therapy. Protein replacement therapy using mRNA targets enzyme deficiency conditions previously reliant on expensive recombinant protein infusions. Clinical programmes for cystic fibrosis, propionic acidaemia, and metabolic disorders are entering Phase 2 trials, representing a significant market inflection that will substantially broaden the mRNA therapeutic addressable market.

Key Market Segmentation

By Vaccine Manufacturing

In-House — Largest Segment (64.3% Market Share, 2025)

In-house vaccine manufacturing dominates with a 64.3% share in 2025, as major pharmaceutical companies including Moderna, BioNTech, and Pfizer prioritize proprietary manufacturing control to protect mRNA intellectual property, ensure quality oversight, and maintain supply chain flexibility. These three companies have collectively invested over USD 8 Billion in dedicated in-house mRNA manufacturing infrastructure since 2020. In February 2026, Ethris announced a strategic collaboration with the German Center for Infection Research (DZIF) to develop next-generation mRNA vaccines with advanced stability and targeted delivery, further illustrating the in-house manufacturing model's continued expansion.

Out-Sourced

Outsourced manufacturing (35.7%) is expanding as CDMO capabilities improve, offering smaller biotech firms access to validated mRNA production without capital-intensive infrastructure investment.

By Application

Infectious Disease — Largest (38.4% Market Share, 2025)

Infectious Disease applications lead the mRNA Vaccines and Therapeutics Market Share with a 38.4% share, reflecting ongoing COVID-19 booster programmes, RSV vaccine rollouts, and advancing influenza mRNA clinical programmes. In August 2025, the FDA approved Pfizer-BioNTech's LP.8.1-adapted COVID-19 vaccine, reinforcing the segment's commercial leadership. Emerging infectious disease threats — including Zika virus disease outbreaks across India in 2024 — further highlight the urgent need for scalable mRNA-based vaccine solutions.

Cancer

Cancer (28.6%) is the fastest-growing application, driven by personalized mRNA cancer vaccine pipelines from Moderna (mRNA-4157) and BioNTech (BNT111, BNT122). Moderna's mRNA-4157 demonstrated 49% reduction in melanoma recurrence risk in Phase 2b trials in combination with Keytruda.

Gene Editing & Protein Replacement

Gene Editing (18.4%) and Protein Replacement (14.6%) segments are gaining traction through advancing clinical programmes in cystic fibrosis, metabolic disorders, and enzyme-deficiency conditions — diversifying the market beyond infectious disease vaccines.

By End-User

Hospitals and Clinics — Largest Segment

Hospitals and clinics represent the dominant end-user segment given their central role in vaccine administration, oncology treatment, and clinical trial execution. Research organizations follow as key end-users driving pipeline development across preclinical and clinical mRNA programmes globally.

Regional Market Analysis

Leading Players in the mRNA Vaccines and Therapeutics Industry

The global mRNA vaccines and therapeutics competitive landscape is led by a concentrated group of multinational pharmaceutical and biotechnology companies. Key companies covered in the IMARC Group report include:

●        Moderna, Inc. — Global Leader: Spikevax, mRESVIA (RSV), mRNA-4157 (cancer vaccine)

●        BioNTech SE — Global Leader: Comirnaty, BNT111 (melanoma), personalized cancer vaccine pipeline

●        Pfizer Inc. — Global Leader: Comirnaty, LP.8.1-adapted COVID-19 vaccine (FDA approved August 2025)

●        GSK plc — Full mRNA pipeline control via CureVac licensing agreement (July 2024); respiratory focus

●        Arcturus Therapeutics — First approved self-amplifying mRNA COVID vaccine (EU, 2025); saRNA platform innovator

●        Sanofi — USD 3.2B Translate Bio acquisition; mRNA Center of Excellence; modRNA platform

●        Merck & Co. — Co-development of mRNA-4157/V940 + KEYTRUDA for personalized cancer immunotherapy

The report includes competitive analysis covering market structure, player positioning, top winning strategies, competitive dashboard, and a company evaluation quadrant.

Latest Industry Developments

August 2025 – Pfizer-BioNTech

The FDA approved Pfizer-BioNTech's LP.8.1-adapted COVID-19 vaccine, demonstrating the mRNA platform's capacity for rapid viral strain adaptation and reinforcing regulatory confidence in next-generation mRNA vaccine design for evolving pathogens.

July 2025 – NIST Reference Material Launch

NIST launched RGTM 10202 FLuc mRNA, a reference material for quality assessment of mRNA therapeutics, supporting standardization across laboratories and accelerating regulatory harmonization for LNP-formulated mRNA therapeutics globally.

February 2026 – Ethris x DZIF Collaboration

Ethris announced a strategic collaboration with the German Center for Infection Research (DZIF) to develop mRNA-based vaccines for infectious diseases, combining Ethris' proprietary mRNA and LNP technologies with DZIF's translational vaccine research expertise to advance next-generation mRNA vaccines with improved stability and broader protection.

January 2023 – BioNTech x UK Government

BioNTech announced a collaboration with the UK government to deliver personalized mRNA cancer immunotherapies for 10,000 patients by 2030, alongside the January 2023 acquisition of InstaDeep Ltd. to bolster AI-powered mRNA drug design capabilities.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Technology, Healthcare, Chemicals, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104

Article source: https://article-realm.com/article/Health-Fitness/85244-mRNA-Vaccines-and-Therapeutics-Market-Size-Share-Industry-Trends-and-Forecast-2026-2034.html